Ils ne constituent pas des preuves scientifiques
In these very high-risk patients, GLP-1 receptor agonists reduce overall mortality, with an NNT of 42 (95% CI, 29 to 84) over five years
10 mg/day vs.placebo
All of these effects can lead to weight loss, but lets get more specific, shall we
During this initial week, you might find that you cannot finish a meal that you previously would have finished entirely, or you may notice that food noisethe constant, intrusive thoughts about what to eat nextbegins to quiet down
Who It's For (Based on Trial Inclusion Criteria) BMI 30 (obesity) OR BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, sleep apnea) Adults ages 1875 (some trials include narrower age ranges) People who have tried lifestyle interventions (diet and exercise) without sufficient weight loss Those with type 2 diabetes seeking both glucose control and weight loss People with obesity-related conditions that would improve with major weight reduction Who Should Avoid Retatrutide Based on trial exclusion criteria and the drug's mechanism, retatrutide is likely not appropriate for: Pregnancy or breastfeeding: Not studied in these populations